NovaBay Pharmaceuticals Inc. (AMEX:NBY) saw an upside of 12.26% to close Tuesday at $0.69 after adding $0.08 on the day. The 5-day average trading volume is 360,880 shares of the company’s common stock. It has gained $0.7926 in the past week and touched a new high 2 times within the past 5 days. An average of 153,855 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 207,092.
NBY’s 1-month performance is -7.13% or -$0.0650 on its low of $0.5800 reached on 08/15/23. The company’s shares have touched a 52-week low of $0.48 and high of $9.38, with the stock’s rally to the 52-week high happening on 01/04/23. YTD, NBY has lost -64.87% or -$1.2650 and has reached a new high 2 times. However, the current price is down -92.70% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NBY stock investors last saw insider trading activity on Dec 06.Kunin Jeffrey (President, DERMAdoctor, LLC) most recently sold 1 shares at $1.81 per share on Dec 06. This transaction cost the insider $2. Chief Product Officer, Kunin Audrey, sold 1 shares at a price of $1.81 on Dec 06. Then, on Nov 21, Chief Product Officer Kunin Audrey sold 5,960 shares at a price of $2.10 per share. This transaction amounted to $12,545.
Valuation Metrics
NBY stock has a beta of 2.81. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.20 while the price-to-book (PB) in the most recent quarter is 0.24.
NovaBay Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 1.40, with the current ratio over the same period at 2.20.. In terms of profitability, the gross margin trailing 12 months is 55.40%. The trailing 12-month EBITDA margin is -49.97%. The firm’s gross profit as reported stood at $7.78 million against revenue of $14.4 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 97.27% to -$4.03 million, while revenue of -$8.21 million was -103.72% off the previous quarter. Analysts expected NBY to announce -$0.55 per share in earnings in its latest quarter, but it posted -$1.27, representing a -130.90% surprise. EBITDA for the quarter stood at more than -$0.85 million. NBY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.45 million, with total debt at $3.04 million. Shareholders hold equity totaling $4.21 million.
Let’s look briefly at NovaBay Pharmaceuticals Inc. (NBY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 56.19% to suggest the stock is trending Neutral, with historical volatility in this time period at 98.44%.
The stock’s 5-day moving average is $0.6237, reflecting a +11.84% or $0.0725 change from its current price. NBY is currently trading -6.48% above its 20-day SMA, -58.48% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +0.72% and SMA200 by-81.34%.
Stochastic %K and %D was 27.20% and 19.86% and the average true range (ATR) pointed at 0.0687. The RSI (14) points at 51.08%, while the 14-day stochastic is at 49.39% with the period’s ATR at 0.0652. The stock’s 9-day MACD Oscillator is pointing at -0.0064 and -0.0190 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for NovaBay Pharmaceuticals Inc. (AMEX: NBY), Ladenburg Thalmann launched coverage with a Buy rating. Analysts offering their rating for NBY stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate NBY as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is NBY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.80 and a high of $9.50, with their median price target at $6.65. Looking at these predictions, the average price target given by analysts is for NovaBay Pharmaceuticals Inc. (NBY) stock is $6.65.
